Are there regional tendencies toward controversial screening practices? A study of prostate and breast cancer screening in a Medicare population

•Prostate and breast cancer screening independent at the regional level.•PSA screening associated with regional intensity of healthcare.•These screening practices should be understood differently for policy implications.•Further work needed to understand factors behind regional variations in screeni...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer epidemiology 2017-10, Vol.50 (Pt A), p.68-75
Hauptverfasser: Raffin, Eric, Onega, Tracy, Bynum, Julie, Austin, Andrea, Carmichael, Donald, Bronner, Kristen, Goodney, Philip, Hyams, Elias S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Prostate and breast cancer screening independent at the regional level.•PSA screening associated with regional intensity of healthcare.•These screening practices should be understood differently for policy implications.•Further work needed to understand factors behind regional variations in screening. Prostate and breast cancer screening in older patients continue to be controversial. Balancing the desire for early detection with avoidance of over-diagnosis has led to competing and contradictory guidelines for both practices. Despite similarities, it is not known how these screening practices are related at the regional level. In this study, we examined how screening PSA and mammography are related within healthcare regions, and, to better understand what may be driving these practices, whether they are associated with local intensity of care. We performed a retrospective cross-sectional study of fee-for-service Medicare beneficiaries in 2012. For each of 306 hospital referral regions (HRRs), we calculated rates of PSA screening for men aged ≥68 years, as well as rates of screening mammography for women aged ≥75 years, adjusted for age and race. Additionally, we determined regional rates of “healthcare intensity”, including spending on tests and procedures, and intensity of end-of-life care. Pearson correlations of adjusted rates were calculated within HRRs. The mean adjusted rate of PSA screening was 22%. The mean age of screened and unscreened patients was 75.0 and 77.4 years, respectively (p
ISSN:1877-7821
1877-783X
DOI:10.1016/j.canep.2017.07.015